Thank you, healthcare workers, for all you do. Your determination to help others is truly inspiring. Please stay safe.
E-Publication E-Publication

HIV Prevention for Black/African American Women: The Use of PrEP in the Primary Care Setting


Maximum Credits:


E-Publication E-Publication


Maximum Credits:
E-Publication E-Publication


Maximum Credits:

Overview: This accredited CME publication explores the behavioral, social, and structural risk factors that contribute to the disproportionate risk of HIV in black/African American heterosexual women and discusses ways to incorporate HIV prevention strategies, including pre-exposure prophylaxis (PrEP), into routine care. Additionally, expert faculty offer insight into the unique challenges that contribute to the increased HIV risk in black/African American women and explain how PrEP can be a powerful tool for HIV prevention in this population.

On October 3, 2019, the United States Food and Drug Administration (FDA) approved emtricitabine 200 mg and tenofovir alafenamide 25 mg (F/TAF; Descovy®) for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV in at-risk adults and adolescents weighing at least 35 kg. F/TAF is not approved for use in individuals with an increased risk of HIV from vaginal sex because its effectiveness has not been studied in this population. At this time, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (F/TDF; Truvada®) is the only FDA-approved medication for pre-exposure prophylaxis for this population.

For more information, refer to the FDA’s press announcement:

CME Information:

Oni J. Blackstock, MD, MHS
Assistant Commissioner
Bureau of HIV/AIDS Prevention and Control
NYC Department of Health and Mental Hygiene
New York, NY
Dr. Blackstock is presenting her own views and does not represent the NYC Department of Health and Mental Hygiene.
Bisola O. Ojikutu, MD, MPH
Assistant Professor of Medicine
Assistant Professor of Global Health and Social Medicine
Harvard Medical School
Associate Physician, Division of Global Health Equity
Brigham and Women’s Hospital
Boston, MA

Activity Planners
Stephanie Larson, PhD
Clinical Content Manager
Baltimore, MD
Rebecca L. Julian, MS, ELS
Senior Manager, Editorial
Baltimore, MD
Samantha Gordon
CME Specialist
Baltimore, MD
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
East Lansing, MI
Stephanie S. Wenick, MPhil
Chevy Chase, MD
Learning Objectives
Upon completion, participants should be able to:

  • Describe the individual, psychosocial, and structural factors contributing to HIV risk among black/African American heterosexual women in the United States
  • Integrate HIV prevention, including PrEP, into the routine care of black/African American women’s reproductive and sexual health

Target Audience
This activity is intended for obstetrician-gynecologists, family planning providers, primary care physicians, and nurses.
Statement of Need
The Centers for Disease Control and Prevention (CDC) estimate that more than 1.1 million Americans have a substantial risk of HIV and should be offered PrEP to prevent HIV infection. Although men who have sex with men (MSM) are the largest subgroup of the high-risk population, heterosexual women—specifically, black/African American heterosexual women—represent a substantial minority of individuals for whom PrEP is warranted. However, PrEP uptake among women is estimated to be approximately 2% of the CDC target, and only one-quarter of women using PrEP are black/African American. Because PrEP has the potential to significantly reduce HIV risk when used as prescribed, it is critically important for women to be aware of their HIV risk, as well as how this self-directed prevention strategy may help them achieve their sexual health goals. It is also essential for clinicians to recognize the rationale for integrating PrEP into routine reproductive healthcare and understand how it can be successfully implemented in this setting. 

Providership Statement
Provided by Med-IQ.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Med-IQ designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Medium/Method of Participation
This CME activity consists of a 0.75-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Initial Release Date: May 30, 2019
Expiration Date: May 29, 2020
Estimated Time to Complete This Activity: 45 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 
Oni J. Blackstock, MD, MHS, has indicated no real or apparent conflicts.
Bisola O. Ojikutu, MD, MPH, has indicated no real or apparent conflicts.

The writer, peer reviewers, and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information        
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email       
System Requirements


  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

ADA Statement
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit:

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Gilead Sciences, Inc.

© 2019 Med-IQ, Inc.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email For technical assistance, please refer to our support manual.

We recently updated our Privacy Notice and Terms of Use.